Horizon Therapeutics Ireland Designated Activity Company — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

2 Recruiting

9 Completed trials

19 Countries active

6 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 4 Phase II: 7

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Sjogren's syndrome 2 Antisynthetase syndrome 1 Idiopathic pulmonary fibrosis 1 Neuromyelitis optica spectrum disorder 1 Idiopathic inflammatory myopathy 1 Dermatomyositis 1 Myasthenia gravis 1 Autoimmune myositis 1 Immunoglobulin G4 related disease 1

Top IMPs

FIPAXALPARANT 3 DAXDILIMAB 2 DAZODALIBEP 2 PREDNISONE 1 VIB1116 1

All trials

11 total

A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Phase III 12 countries DAZODALIBEP
Neuromyelitis Optica Spectrum Disorder Inebilizumab Study in Children and Adolescents Recruiting

2023-510007-22-00 Phase II 5 countries
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Phase III 12 countries DAZODALIBEP
Inebilizumab efficacy and safety in adults with myasthenia gravis Ended

2023-510006-40-00 Phase III 5 countries
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended

2023-508290-81-00 Phase III 6 countries
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended

2023-507680-19-00 Phase II 11 countries VIB1116
A Phase 2 proof of concept study to evaluate the efficacy and safety of daxdilimab in participants with dermatomyositis or anti-synthetase i… Ended

2022-502810-10-00 Phase II 5 countries DAXDILIMAB; PREDNISONE
A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended

2023-509746-35-00 Phase II 7 countries DAXDILIMAB
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509783-23-00 Phase II 9 countries FIPAXALPARANT
A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis Ended

2023-509784-24-00 Phase II 6 countries FIPAXALPARANT
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509782-20-00 Phase II 9 countries FIPAXALPARANT

Showing 1–11 of 11 trials

← All sponsors A–Z